Department of Hematology and Oncology, Krankenhaus Nordwest, Frankfurt am Main, Germany.
Oncology. 2011;80(1-2):130-4. doi: 10.1159/000329063. Epub 2011 Jun 14.
This study was designed to investigate the expression of phosphorylated mitogen-activated protein kinase (p-MAPK/Erk1 and Erk2) and its correlation with outcomes in patients with metastatic gastric cancer.
p-MAPK was detected by immunohistochemistry using monoclonal antibodies in a total of 223 formalin-fixed, paraffin-embedded samples obtained from 156 patients who received first-line chemotherapy in a phase III trial.
p-MAPK was positive in 93 (59.6%) and negative in 63 (40.4%) of the 156 patients evaluated. Similar rates of p-MAPK positivity were found in primaries (53%) and metastatic lesions (61.4%). Overall survival was significantly shorter in p-MAPK-positive patients (13.7 vs. 8.5 months) in the univariate analysis. However, this prognostic value disappeared as a trend in the multivariate analysis (p = 0.1). There was a strong, positive correlation between p-MAPK and the MIB-1 proliferation index, but MIB-1 did not predict outcomes.
p-MAPK expression could be a potential negative prognostic parameter in patients with metastatic gastric cancer treated with chemotherapy.
本研究旨在探讨磷酸化丝裂原活化蛋白激酶（p-MAPK/Erk1 和 Erk2）的表达及其与转移性胃癌患者预后的关系。
采用单克隆抗体免疫组化法检测 223 例经一线化疗的 156 例转移性胃癌患者福尔马林固定、石蜡包埋样本中 p-MAPK 的表达。
在 156 例可评价患者中，93 例（59.6%）为 p-MAPK 阳性，63 例（40.4%）为 p-MAPK 阴性。原发灶和转移灶的 p-MAPK 阳性率相似（分别为 53%和 61.4%）。单因素分析显示，p-MAPK 阳性患者的总生存期明显短于 p-MAPK 阴性患者（13.7 个月比 8.5 个月）。但多因素分析显示，这种预后价值呈趋势但无统计学意义（p=0.1）。p-MAPK 与 MIB-1 增殖指数之间存在强正相关，但 MIB-1 不能预测预后。
p-MAPK 表达可能是接受化疗的转移性胃癌患者的一个潜在负性预后参数。
